Results 201 to 210 of about 23,244 (239)
Some of the next articles are maybe not open access.
Chemerin Tips the Scales in ccRCC to Evade Ferroptosis
Cancer Discovery, 2021Abstract Summary: Obesity is both a risk factor for the development of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC), and a prognostically protective factor for clinical outcomes.
Ed Reznik, Hui Jiang, A. Ari Hakimi
openaire +2 more sources
Science Signaling
Targeting a driver of TBK1 kinase activity may slow the growth of kidney tumors.
openaire +2 more sources
Targeting a driver of TBK1 kinase activity may slow the growth of kidney tumors.
openaire +2 more sources
Abstract IA025: Nuclear speckles in ccRCC
Cancer ResearchAbstract Inside the cell nucleus, nuclear speckles are a predominant type of nuclear body present in the cells throughout our bodies. While first observed by Ramon y Cajal over 100 years ago, speckles have only recently been recognized as a major layer of gene regulation that boosts gene expression by assisting multiple steps of RNA ...
Sana Mir +3 more
openaire +1 more source
The Warburg effect in hominis: isotope-resolved metabolism in ccRCC
Nature Reviews Urology, 2018A recently published study has evaluated metabolism in human clear cell renal carcinomas (ccRCCs) using intraoperative [13C]glucose infusion during surgical procedures. The findings demonstrate aerobic glycolysis and repression of the Krebs cycle, confirming the existence of the Warburg effect in ccRCC tumours in vivo.
Daniel R, Crooks, W Marston, Linehan
openaire +2 more sources
New insights into the ccRCC microenvironment
Nature Reviews Nephrology, 2021openaire +2 more sources
HIF2α Antagonism Has Antitumor Activity in Advanced ccRCC
Cancer Discovery, 2018Abstract The HIF2α antagonist PT2385 achieved responses in 14% of patients with heavily pretreated ccRCC.
openaire +2 more sources
Belzutifan: A Breakthrough in Targeted Therapy for ccRCC
Theoretical and Natural ScienceBelzutifan, a novel orally bioavailable small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α), represents a mechanistically distinct and clinically promising therapy for clear cell renal cell carcinoma (ccRCC), particularly in patients with von Hippel–Lindau (VHL) disease.
openaire +1 more source